Skip to content

Efficacy and Safety Study of a Percussion Device to Mobilise Sputum From Respiratory Passage

A Prospective, Cross-over Randomized Trial to Assess the Efficacy and Safety of Mechanical Percussor LEGA Compared With Conventional Chest Physiotherapy in Adults With Chronic Bronchiectasis or Chronic Obstructive Pulmonary Disease (COPD

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01480882
Acronym
LEGA
Enrollment
20
Registered
2011-11-29
Start date
2011-12-31
Completion date
2012-06-30
Last updated
2012-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)

Keywords

Manual percussion, Mechanical percussion, Chronic bronchiectasis, Chronic Obstructive Pulmonary Disease, Wet sputum weight, Dry sputum weight

Brief summary

A Malaysian company by name Formedic Technologies SDN BHD has devised a hand held machine which is supposed to mimic the chest percussion performed by professional physiotherapist to mobilize sputum through the respiratory passage. The aim of this study is to compare the effectiveness and safety of this mechanical percussion device in the treatment of airway clearance with conventional chest physiotherapy carried out by qualified physiotherapists in patients suffering from bronchiectasis or Chronic obstructive Pulmonary disease (COPD).

Detailed description

This study will compare the amount of sputum expectorated during the two procedures and not intended to look at the clinical improvement of the patient.

Interventions

PROCEDUREConventional Chest Physiotherapy (CCPT)

Conventional chest percussion will be applied for a duration of 15 minutes.

DEVICEMechanical percussion (LEGA)

Mechanical chest percussion will be delivered by a device for 15 minutes.

Sponsors

Penang Hospital, Malaysia
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult patients \> 18 years of age 2. Chronic sputum expectoration-(producing \>30ml/day of sputum at baseline) 3. Clinical diagnosis of bronchiectasis or COPD 4. Not carrying out regular chest physiotherapy (for the purposes of this study this will be defined as less than two occasions per week) 5. Clinically stable disease (defined as no requirement for antibiotics in the 4 weeks preceding study entry). 6. FEV1 of \> 35% of the predicted value in COPD patients

Exclusion criteria

1. Primary diagnosis of asthma; 2. Active sarcoidosis 3. Active Pulmonary tuberculosis. 4. History of brittle bones, 5. History of broken ribs in the past one year. 6. History of severe osteoporosis 7. Bleeding from the lungs or haemoptysis 8. Experiencing intense pain in the thoracic region 9. Clinical suspicion of increased intracranial pressure. 10. Have head or neck injuries 11. Have collapsed lungs or a damaged chest wall; 12. Recent myocardial infarction, unstable angina and stroke (Within 6 months prior to enrollment) 13. Have a pulmonary embolism or lung abscess; 14. Have an active hemorrhage 15. Have injuries to the spine 16. Have open wounds or burns in the thoracic region 17. Have had recent surgery (Within six months prior to enrollment.) 18. Any systemic steroids within 4/52 prior to enrollment 19. Any antibiotics within 4/52 prior to enrollment

Design outcomes

Primary

MeasureTime frameDescription
Comparing the 'wet weight' and 'dry weight' of the sputum expectorated during 20 minutes of the two procedures.6 daysThe patients will be instructed to cough out the sputum into a preweighed container during the 15 minutes of the procedure(Manual or mechanical percussion)and 5 minutes after the procedure.Container will be weighed to get the wet weight of the sputum then will be dried in a laboratory oven at 60degree c for 48 hours and weighed again to get the dry weight of the sputum

Secondary

MeasureTime frameDescription
Change in FEV1 and FVC before and after the two methods of therapy15 minutes after completion of the procedure compared to baselineAny changes in the lung function will be measured as - FEV1 (%predicted) and FVC (%predicted)
Changes in pulse, blood pressure and respiratory rate15 minutes after completion of treatment compared to baselineMonitoring of Pulse, blood pressure, respiratory rate, skin colour and patients reaction to treatment.
Patient preferenceAfter completing 6 days of participation in the studyPatients will be participating in the study for 6 days. On the 6th day after completion of treatment they will be required to answer a simple questionnaire to find out if they prefer one procedure over the other and why.

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026